Navigation Links
FDA Starts Safety Review of Autoimmune Disorder Drugs
Date:6/4/2008

Reports of increased cancer risk among young users of TNF blockers prompts action

WEDNESDAY, June 4 (HealthDay News) -- U.S. health officials have started a safety review of a class of drugs known as tumor necrosis factor (TNF) blockers, which are widely prescribed to treat autoimmune disorders such as rheumatoid arthritis, juvenile rheumatoid arthritis and Crohn's disease.

The announcement did not come as a surprise, as experts have long debated the risk-benefit profile of the drugs without coming to any consensus.

Among the chief concerns being investigated by the U.S. Food and Drug Administration are whether the drugs are associated with the development of cancer, especially lymphoma, in children and young adults being treated for rheumatoid arthritis or Crohn's disease. The agency is investigating about 30 reports of cancer in this younger age group submitted between 1998, after the approval of the first TNF blocker, through April of this year. TNF blockers have also been linked to an increased risk of infection.

"I think it's a fair thing to say this is an area of ongoing concern that has not been resolved. It's not something new," said Dr. Chaim Putterman, chief of the division of rheumatology at Montefiore Medical Center and Albert Einstein College of Medicine in New York City. "[The drugs] were approved in adults, and more drugs are coming out, and everyone would prefer an indication in children, so the FDA has decided to clear it. It has always been a concern, and it's something that should be clarified."

Four TNF blockers are currently approved in the United States: Enbrel (etanercept), Humira (adalimumab), Remicade (infliximab) and Cimzia (certolizumab). Remicade is approved for use in children with Crohn's disease. Enbrel and Humira are approved to treat children with juvenile rheumatoid arthritis, according to the FDA.

The FDA review is focusing on the first three. All four are approved for multiple indications.

TNF blockers work by dampening the immune system, which becomes hyperactive in patients with rheumatoid arthritis.

The drugs have clear benefits, according to experts, and have revolutionized the treatment of some of these diseases.

"One of the reasons that these medications have such a market despite the concerns is that they are so remarkably effective," Putterman said. "There are not only subjective benefits but a tremendous amount of objective evidence, not only in inflammation and patient symptoms, but also in disease progression. These drugs have really addressed a previously unmet need."

"These drugs are probably the most important advance in the treatment of rheumatoid disorders in the last 20 to 30 years. They dramatically improve certain forms of crippling arthritis and almost stop them. Some people go from being in a wheelchair [to] jumping up and walking around," said Dr. Stephen Lindsey, head of rheumatology at Ochsner Health Service in Baton Rouge, La. "They're being used earlier and earlier, because they're so good. I think the FDA is being cautious. I think it's smart. What are the risks of a child being crippled and non-functioning versus the risk of cancer? Maybe, in odd cases, we need to think more and not jump in with all four limbs."

The increased risk for cancer may also be a result of factors other than the drug. "The signal [for cancer] has not been a dramatic one," Putterman said. "There are confounding factors in rheumatoid arthritis patients, which can make interpretation of the data more difficult."

One confounding factor is that rheumatoid arthritis patients, independent of treatment, have a higher risk of some cancers, and some patients have also been treated with methotrexate, a chemotherapy agent that has a known association with lymphoma.

And then there's the conflicting scientific evidence. One 2006 study reported that concerns about TNF blockers causing cancer were unfounded. But earlier this year, a review of the research concluded the risk may be real.

"TNF plays an important role in immune surveillance and, by blocking it, you might be interfering with the body's own defenses," Putterman said.

The FDA has requested that makers of TNF blockers approved for use in children and young adults supply information about all reported cases of cancer in children and young adults taking the drugs.

The maker of Cimzia, UCB Inc., must conduct a study looking at the long-term risks of this drug. That study will begin in 2009, and will take about a decade to complete.

In the meantime, the FDA has asked health-care professionals to weigh the possible risks against the benefits when prescribing TNF blockers.

More information

Read about TNF blockers U.S. Food and Drug Administration.



SOURCES: Chaim Putterman, M.D., chief, division of rheumatology, Montefiore Medical Center and Albert Einstein College of Medicine, New York City; Stephen Lindsey, head, rheumatology, Ochsner Health Service, Baton Rouge, La.; June 4, 2008, U.S. Food and Drug Administration statement


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Haemacure Achieves Major Milestone - Starts Processing Plasma in Its New Fractionation Facility
2. Heart Disease Starts Early in Life
3. Mike Turner, Virginia Congressional Candidate, Starts Healthcare Countdown
4. Alzheimers Starts Earlier for Heavy Drinkers, Smokers
5. Gerresheimer Starts the Year Successfully in 2008
6. Kronos Optimal Health Company Aims to Stop Diabetes Before It Starts
7. April is National Child Abuse Prevention Month: Learn 24 Ways to Prevent Child Abuse ... Before it Starts
8. Healing Starts With Us National Campaign Commits to Battling Depression - By Any Means Necessary
9. The Gender Divide Starts Over Dinner
10. The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington, Ruby Dee, MoNique, Terry McMillan, Rev. Al Sharpton and Others
11. Taking Care of Your Skin Starts From Within
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Starts Safety Review of Autoimmune Disorder Drugs
(Date:3/22/2017)... ... March 22, 2017 , ... ... a PCSK9 inhibitor prior authorization (PA) form for prescribers to improve patients’ access ... of the helpful tools published as part of the article entitled “PCSK9 ...
(Date:3/22/2017)... ... March 22, 2017 , ... Soriant recognizes that ... bypasses that. Healthcare facilities across the country are always forced to focus ... and hospitals, across the country, an efficient and quick way to estimate savings ...
(Date:3/22/2017)... ... March 22, 2017 , ... In ... and print media enterprise focused on cancer patients, cancer centers and advocacy groups, ... special 12-part educational video series, “No Ifs, Ands, or Butts,” that focuses on ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... that its digital marketing solutions have enabled Children’s Hospital of The King’s Daughters ... , Recognizing the value of a digital marketing approach, the 206-bed pediatric ...
(Date:3/22/2017)... ... 2017 , ... An intensive search of the medical literature has revealed no ... PhD. He says investigating this possibility, is important because Miami-Dade in 2016 ... infections with HIV. , His findings appear on Analizir.com. . Dr. ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Respiratory care devices Market is ... next decade to reach approximately $38.27 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/22/2017)... NEW YORK , March 22, 2017 /PRNewswire/ ... pharmaceutical industry, Chinese pharmaceutical packaging market size increased ... during 2010-2016. From 2017 to 2021, the market ... 10% and is expected to outnumber RMB140 billion ... two-child policy, the rapid development of biological agents ...
(Date:3/22/2017)... FALLS, N.J. , March 22, 2017  CANTEL MEDICAL ... Jorgen B. Hansen , President and CEO, will be presenting ... Conference at the Westin Grand Central Hotel in ... Wednesday, April 5, 2017 at 3:00 p.m. ET. In addition, ... day. A live audio webcast will be ...
Breaking Medicine Technology: